Navigation Links
PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
Date:4/2/2008

nt, as set forth above, to accommodate the change in circumstances.

BroadOak Partners, LLC and Piper Jaffray Ltd. acted as financial advisors to PharmAthene and Avecia, respectively, in connection with the transaction.

rPA Anthrax Vaccine

Avecia's rPA vaccine, which has completed Phase II clinical testing, is a second generation rPA anthrax vaccine for use against human anthrax infection.

In February 2008, the Department of Health and Human Services (DHHS) issued a formal solicitation (Request for Proposals) for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile (SNS). The solicitation outlines a requirement to procure 25 million doses of an rPA anthrax vaccine.

"There is currently an unmet need for a second generation anthrax vaccine that offers the potential for improved safety and convenience," said Mr. Wright. "We believe Avecia's vaccine is well positioned to meet this requirement, as it is a highly purified recombinant form of a single protein -- protective antigen (PA), which is produced using standard biotechnology processes. In preclinical and clinical studies the vaccine was shown to produce a vaccine-induced antibody response and was safe and well tolerated. If these results are confirmed in future studies, we believe this vaccine could prove to be a superior choice for procurement in the Strategic National Stockpile for civilian defense against anthrax threats."

About PharmAthene, Inc.

PharmAthene (Amex: PIP) was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead programs include Valortim(TM) for the prevention
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PharmAthene Reports Year-End 2007 Financial Results
2. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program
3. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
4. PharmAthene to Delay Release of Full Year 2007 Financial Results
5. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
6. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
9. PharmAthene to Present at the BIO CEO & Investor Conference 2008
10. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
11. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, a website ... are used solely in scientific experiments, is currently celebrating ... in business, Maxim Peptide, which was created by the ... new and updated website that now features a special ... been updated with fascinating articles about peptide research, including ...
(Date:7/11/2014)... 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) ... (eslicarbazepine acetate) for use as a once-daily adjunctive therapy ... epilepsy who are not satisfactorily controlled with conventional therapy. ... patients under 18 years of age. ... and according to Epilepsy Canada, it affects 0.6% of ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Deep ... Century Medicine Forum on ‘Commercialising Longevity Research’ and ... entrepreneurs to the London Bioscience Innovation Center for ... Foundation and Aging Analytics Ltd. The meeting highlighted ... in translational research for age-related disease, as well ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 OMICS Group’s ... techniques during 18-20 August, 2014 at Double Tree by ... the recent developments in Analytical & Bioanalytical research methods ... , Speaking on this occasion, Dr. Srinubabu Gedela, MD ... Acta conference is a remarkable one in bringing a ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... DIEGO, Dec. 15, 2010 Ocera Therapeutics, Inc. ... evaluating the safety and pharmacokinetics of OCR-002 (ornithine ... liver cirrhosis.  OCR-002 recently received Orphan Drug status ... Food and Drug Administration for the treatment of ...
... , This release is available in ... scientists have identified the primary site where the virus ... This discovery could lead to development of new ... contagious and sometimes fatal viral disease of cloven-hoofed animals ...
... small cabinet the size of a dorm refrigerator in one of ... bottles under the cool light of red, blue and green LEDS. ... of champions. The soup is colored by a strain of ... produced by their nearest competitorsin part because of their unique genetic ...
Cached Biology Technology:Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy 2Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy 3USDA scientists discover how foot-and-mouth disease virus begins infection in cattle 2Champion hydrogen-producing microbe 2Champion hydrogen-producing microbe 3Champion hydrogen-producing microbe 4
(Date:7/11/2014)... University of Chicago is creating a new professorship ... the University,s Institute for Molecular Engineering and the ... donation from the Millicent and Eugene Bell Foundation., ... reside within the Institute for Molecular Engineering. That ... project at the MBL,s Eugene Bell Center for ...
(Date:7/11/2014)... "mouse TRAP" to capture the early signs of kidney ... the Journal of Clinical Investigation . Their new ... extract cellular and genetic information from a variety of ... Institute for Medical Research in 2008, TRAP involves attaching ... of the cell type of interest. Scientists can then ...
(Date:7/11/2014)... 10, 2014---A team of researchers from The Chinese University ... a gene of wild soybean linked to salt tolerance, ... in saline soil. This study published online in ... novel genomic information for crop improvement. , Soybean is ... and human selection, cultivated soybeans have less genetic diversities ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2BGI reports a novel gene for salt tolerance found in wild soybean 2
... Richfield Co. was tasked with cleaning up a major superfund ... Texas A&M University professor, got a call to assist the ... crop science professor, spent two years leading a Texas A&M ... of copper mining, mineral processing and smelting in the Anaconda, ...
... In the first side-by-side tests of a half-dozen palladium- and ... scientists have found that palladium destroys TCE far faster than ... cases. The results will appear in a new study ... B: Environmental. TCE, or trichloroethene, is a widely ...
... 2012: Element Six, the world leader in synthetic ... of Warwick,s Departments of Chemistry and Physics, have ... properties of metal-like boron-doped synthetic diamond. The research ... properties while retaining the full strength and durability ...
Cached Biology News:Mining cleanup benefits from Texas A&M expertise 2Mining cleanup benefits from Texas A&M expertise 3Palladium-gold nanoparticles clean TCE a billion times faster than iron filings 2Synthetic diamond steps closer to next generation of high performance electrochemical applications 2Synthetic diamond steps closer to next generation of high performance electrochemical applications 3
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
Edited by D.M. Gersten (1996) Provides comprehensive descriptions of the techniques available for analytical gel electrophoresis of proteins and offers clear step-by-step protocols for all of the m...
... M. Walker (1996) • This book ... for studying proteins and peptides. Each ... step-by-step instruction, timesaving troubleshooting tips, alternative ... of reagents and suppliers. Topics covered ...
...
Biology Products: